Scientific Industries Inc

and welcome to the Scientific Industries First Quarter Fiscal Year 2025 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Joe Dorme, Managing Partner. Please go ahead.

Thanks, Michael. Good morning, and thank you all for joining us today to review Scientific Industries' first quarter 2025 financial results for the period ended March 31st, 2025. With us today on the call are Helena Santos, Chief Executive Officer, Daniel Donadie, CEO of SBI, and John Moore, Chairman. After the conclusion of today's prepared remarks, we'll open the call for questions. Before we begin with prepared remarks, I would like to remind everyone, certain statements made by the management team of scientific industries during this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Except for the statements of historical fact, this conference call may contain forward-looking statements that involve risks and uncertainties, some of which are detailed under risk factors in documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended December 31, 2024. Forward-looking statements speak only as of the date the statements were made. The company can give no assurance that such forward-looking statements will prove to be correct. Scientific Industries does not undertake and specifically disclaims any obligation to update any forward-looking statements except as required by law. Now I'd like to turn the call over to Helena Santos, CEO of Scientific Industries. Helena?

Thank you, Joe, and thank you everyone for joining us today. We entered our calendar year 2025 in our first quarter in very turbulent macroeconomics environment, which is full of uncertainties and to some extent still exists today. What was our focus during quarter number one in this fiscal year? Our focus was, one, securing additional financing to allow us to focus on the growth of our bioprocessing business, and two, and just as important, was navigating the current uncertain environment that we have been facing over the past few months. Regarding number one, thank you to our unwavering support of our existing shareholders, we were able to successfully raise $1.5 million, and this enables us to continue the important development work of our new SBI DOTS multi-parameter sensor platform as we prepare for an important launch of our first-in-class optical pH sensor and high-performance liquid injection system at the end of this year. Mr. Daniel Donadio will provide further detail on our efforts in a few minutes. Q1 2025 was a good quarter for benchtop lab equipment, and this was despite all the challenges that we all know of. Our Genie brand products did well, with a notable shift towards U.S.-based customers versus overseas customers. We began shipping our first Vivid workstation. and we put out several units at key accounts, and this was for real-world pill counter training data for our future AI-enabled pill visit counter, which will be a pioneer in the industry when we launch it in January 2026. For our bioprocessing business segment, our revenues came in quite low as we encountered headwinds and closing the deals. And this was due to disruptions in financing of small biotech startup customers, challenges in the academic markets due to government funding, particularly in the United States, tariff-related uncertainties and the pharmaceutical sector, and also the fact that since we are focusing on the male cell culture market customers, the sales cycle just tends to be longer because the trial periods tend to take longer. than our traditional microbial market customers. But as Mr. Donadio will point out, we are confident that we will be able to capitalize on a record number of leads and opportunities and close those deals in the latter part of the year. And this is expected to already start in our Q2 as we see activity starting to pick up. And with that, I thank you. And I will turn it over to Daniel Donadie. Daniel?